Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.
USOR 24198 - Ph3 study of Bleximenib, Venetoclax & Azacitidine in participants with AML
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy
Disease Types: Leukemia
Available at: Arlington Heights, Chicago, Niles